Zugl.: Aachen, Techn. Hochsch., Diss., 2006.

Zugl.: Berlin, Freie Univ., Diss., 2007

Teilw. zugl.: Heidelberg, Universiẗat, Diss.

Zugl.: Bamberg, Univ., Diss., 2009

Zugl.: Bamberg, Universiẗat, Diss., 2009.

Thesis (doctoral)--Technische Hochschule, Aachen, 2000.

Es gibt Hinweise darauf, dass der weibliche Zyklus in unterschiedlicher Weise die Barrierehomöostase beeinflusst. Zudem wurden Assoziationen zwischen ausgeprägtem psychischen Stress und der Barrierehomöostase dokumentiert sowie die beeinflussende Wirkung des Serumcortisols diskutiert. In dieser Arbeit wurde getrennt voneinander untersucht, ob die Irritabilität der epidermalen Barriere nach chemischer und physikalischer Irritation vom Menstruationszyklus bzw. vom "alltäglich" wahrgenommenen psychischen Wohlbefinden oder vom ausgeschütteten Cortisol abhängig ist. Methode: Die Barrierefunktion wurde in verschiedenen Zyklusphasen (späte Follikel-, späte Lutealphase) hautphysiologisch erfasst; die Hautreaktion visuell beobachtet. Zur Irritation wurden Natriumlaurylsulfat, Natronlauge, Isopropylalkohol, Pyramidenarray und Tapestripping eingesetzt. Die Studie wurde an hautgesunden Probandinnen mit regelmäßigem Zyklus durchgeführt, die keine hormonellen Kontrazeptiva verwendeten. Das psychische Befinden wurde mittels Fragebogen dokumentiert, die Cortisolkonzentration im Speichel erfasst. Ergebnis: Es fanden sich nach 20-minütiger NaOH-Exposition in der Lutealphase hoch signifikant höhere TEWL-Werte. Bei den anderen Irritationen fanden sich keine signifikanten Unterschiede. Der Vergleich des Zeitpunktes des höheren vs. des niedrigeren psychische Wohlbefindens sowie der Vergleich der Zeitpunkte der höheren vs. der niedrigeren Cortisolwerte ergab keine relevanten Unterschiede. Schlussfolgerung: Die Ergebnisse liefern Hinweise darauf, dass bei einigen angewendeten Irritationsverfahren eine mit dem Zyklus assoziierte Variation der Irritabilität existiert, wobei die Reaktion des Hautorgans auf den schädigenden Einfluss in der lutealen Phase stärker als in der Follikelphase ist. Dagegen scheint eine Assoziation zwischen dem "alltäglichen" psychischen Befinden bzw. dem Speichelcortisol und der Irritabilität bzw. der Regeneration nicht gegeben.

The World Health Organization-Composite International Diagnostic Interview (WHO-CIDI) is a highly structured interview for the assessment of mental disorders, based on the definitions and criteria of the fourth edition of the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Over the past decade it has become evident that the CIDI does not sufficiently address the assessment needs of women. Women are affected by most mental disorders, particularly mood and anxiety disorders, approximately twice as frequently as men. Women-specific disorders, such as Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), psychiatric disorders during pregnancy and postpartum as well as during the perimenopause, menopause and beyond are not addressed by the standard CIDI diagnostic modules. In addition, the CIDI in its current form does not address the potential effect that female reproductive milestones may have on diagnosis, treatment and prevention of mental disorders in women. Our aim was to develop a new women specific platform (CIDI-VENUS; CIDI-V) to be embedded in the existing CIDI that will address the above mentioned current deficiencies. Guided by a team of experts in the field of Women’s Mental Health from Canada and Germany the following modules were developed: 1) A complete menstrual history and comprehensive contraceptive history with a link to the Premenstrual Symptoms Screening Tool (PSST). 2) A complete perinatal history of pregnancies, miscarriages, terminations, still births, death of a child, with details of current pregnancy including gestation and expected date of confinement, labour history and breastfeeding, history of tobacco, alcohol, and other substance use including prescription drugs during pregnancy and postpartum, a section on specific phobias and on recurrent obsessive/compulsive thoughts/behaviours (OCD) related to the baby with a link to the Perinatal Obsessive-Compulsive Scale (POCS), as well as a link to the Edinburgh Postnatal Depression Scale (EPDS). 3). A detailed history of use of hormone therapy (e.g. pills, patches, implants, etc.) with a focus on (peri-) menopausal women, differentiating between physical and psychological symptoms with a link to the Menopause Visual Analogue Scales (M-VAS) and to the Greene Climacteric Scale. 4) An iterative module concluding each CIDI section to specify the course of mental disorders during the reproductive stages and menopausal transition. While retaining core diagnostic sections and diagnostic algorithms, the CIDI-V is enriched by women-specific diagnostic modules, providing a wealth of clinically relevant information about women’s mental health, not available anywhere else in our current psychiatric diagnostic instruments.

The World Health Organization-Composite International Diagnostic Interview (WHO-CIDI) is a highly structured interview for the assessment of mental disorders, based on the definitions and criteria of the fourth edition of the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Over the past decade it has become evident that the CIDI does not sufficiently address the assessment needs of women. Women are affected by most mental disorders, particularly mood and anxiety disorders, approximately twice as frequently as men. Women-specific disorders, such as Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), psychiatric disorders during pregnancy and postpartum as well as during the perimenopause, menopause and beyond are not addressed by the standard CIDI diagnostic modules. In addition, the CIDI in its current form does not address the potential effect that female reproductive milestones may have on diagnosis, treatment and prevention of mental disorders in women. Our aim was to develop a new women specific platform (CIDI-VENUS; CIDI-V) to be embedded in the existing CIDI that will address the above mentioned current deficiencies. Guided by a team of experts in the field of Women’s Mental Health from Canada and Germany the following modules were developed: 1) A complete menstrual history and comprehensive contraceptive history with a link to the Premenstrual Symptoms Screening Tool (PSST). 2) A complete perinatal history of pregnancies, miscarriages, terminations, still births, death of a child, with details of current pregnancy including gestation and expected date of confinement, labour history and breastfeeding, history of tobacco, alcohol, and other substance use including prescription drugs during pregnancy and postpartum, a section on specific phobias and on recurrent obsessive/compulsive thoughts/behaviours (OCD) related to the baby with a link to the Perinatal Obsessive-Compulsive Scale (POCS), as well as a link to the Edinburgh Postnatal Depression Scale (EPDS). 3). A detailed history of use of hormone therapy (e.g. pills, patches, implants, etc.) with a focus on (peri-) menopausal women, differentiating between physical and psychological symptoms with a link to the Menopause Visual Analogue Scales (M-VAS) and to the Greene Climacteric Scale. 4) An iterative module concluding each CIDI section to specify the course of mental disorders during the reproductive stages and menopausal transition. While retaining core diagnostic sections and diagnostic algorithms, the CIDI-V is enriched by women-specific diagnostic modules, providing a wealth of clinically relevant information about women’s mental health, not available anywhere else in our current psychiatric diagnostic instruments.

No description available.